Please click on the photo for brief biodata
Professor Dr Mohamad Mohty
Saint -Antoine Hospital, Sorbonne University, Paris, France
Saint -Antoine Hospital, Sorbonne University, Paris, France
A full Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University in Paris, France. He obtained his medical degree from the University of Montpellier, France, and his Ph.D. from the University of Marseille, France. He is also head of a translational research team (Inserm) at the Saint-Antoine Research Centre in Paris. Dr. Mohty is the past president of the European Society for Blood and Marrow Transplantation (EBMT) and the current chairman of the Acute Leukemia Working Party of the EBMT. He is also the founder and chairman of the International Academy for Clinical Hematology (IACH) and board member of the EBMT and the Intergroup Francophone du Myeloma (IFM). In addition to publishing more than 780 peer-reviewed articles in the field of stem cell transplantation, leukemia, and myeloma, Dr. Mohty also serves as Editor-in-Chief of the journals Bone Marrow Transplantation and Clinical Hematology International. He also serves as an editor, board member, and/or reviewer across numerous other reputable journals.
Professor Dr Cameron Turtle
Fred Hutchinson Cancer Research Center, Washington, United States
Fred Hutchinson Cancer Research Center, Washington, United States
Professor Dr Cameron Turtle is a licensed physician and serve as an Attending Physician on the HCT service and the Immunotherapy Service at FHCRC, Seattle Cancer Care Alliance (SCCA), and the University of Washington Medical Center. He completed medical and specialist training in Australia and a 6-year training program of the Joint Specialists Advisory Committee, which includes Fellowships of the Royal Australasian College of Physicians and the Royal College of Pathologists of Australasia in hematooncology.
Professor Dr Christopher Ward
Royal North Shore Hospital, Sydney, Australia
-1.jpg)
Royal North Shore Hospital, Sydney, Australia
Professor Ward is a clinical haematologist based at Royal North Shore hospital, with an academic appointment in the Faculty of Medicine, University of Sydney. His clinical interests are in coagulation, particularly venous thromboembolism and platelet disorders, myeloproliferative disorders and myeloma. He runs the thrombosis and anticoagulation clinics at RNS and supervises outpatient management of venous thrombosis. Prof Ward is the lead investigator at RNS for clinical trials of new anticoagulants and therapies for thrombocytopenia. As Director of Research for the Department of Haematology and Transfusion Medicine, he supervises several research groups investigating platelet function disorders, hypercoagulable states including cancer-related thrombosis, myeloproliferative disorders and the development of stem cell-based therapies. Professor Ward coordinates undergraduate teaching in the Department and supervises a number of postgraduate students in research and clinical trial posts. He is active in regional and international professional societies, with leadership positions in the International Society of Thrombosis and Haemostasis and American Society of Hematology. Special interests in thrombophilia, platelet disorders and vascular biology, myeloma.
Professor Dr Constantine Tam
St Vincent’s Hospital, Melbourne, Australia
St Vincent’s Hospital, Melbourne, Australia
Professor Constantine (Con) Tam is Head of Lymphoma Service at Alfred Health, and Professor of Haematology at Monash University. Con received his M.B.B.S.(Hons) and M.D. degrees from the University of Melbourne. After dual training in Haematology and Haematopathology, Con completed his Leukemia Fellowship at MD Anderson Cancer Centre in Houston, Texas. Prior to moving to the Alfred, Con served as Disease Group Lead for Low Grade Lymphoma and CLL at Peter MacCallum Cancer Centre & Royal Melbourne Hospital for over 10 years. Con is passionate about developing new treatment for blood cancers. He is the global lead for the BTK inhibitor zanubrutinib, and oversaw its development from the first human dosed (in Melbourne) to successful international licensing studies worldwide. Con designed and performed the first global study to combine ibrutinib and venetoclax, publishing the results in the New England Journal of Medicine 5 years after inception. In 2015, he became the Australian lead for the pivotal study of Tisagenlecleucel in diffuse large B-cell lymphoma, leading to public funding for CAR T-cells as standard treatment in Australia. The publication record for Con includes 240 peer-reviewed papers in New England Journal of Medicine, Lancet, Journal of Clinical Oncology, Blood and other top-tier journals. His work has been cited >17,000 times in the literature. Con is the current Lymphoma Editor for Blood Advances.
Professor Dr Erica Wood
Monash University, Melbourne, Australia
Monash University, Melbourne, Australia
Professor Erica Wood is a Transfusion Medicine Specialist, and Head of the Transfusion Research Unit at DEPM. She is an NHMRC Leadership Fellow (Level 2, 2020-2024). Erica also works as a Consultant Haematologist at Monash Health and holds an honorary Consultant Haematologist appointment at Peter MacCallum Cancer Centre/Victorian Comprehensive Cancer Centre. Erica is a member of the World Health Organization's Expert Advisory Panel on Transfusion Medicine, and the WHO Guideline Development Group on Anaemia. She has served as a WHO regional advisor in blood safety. Erica is immediate past president and member of the Board of the International Society of Blood Transfusion and a member of several of its working parties, including clinical practice, haemovigilance and transfusion-transmitted infections. Erica is the immediate past-President of the International Haemovigilance Network, promoting haemovigilance world-wide and supporting haemovigilance systems in their work. Erica is also past-President of the Australian and New Zealand Society of Blood Transfusion and in 2016, delivered the Ruth Sanger Oration at the Society's Annual Scientific Meeting - the Society's highest honour. She is presently a member of the ANZSBT Research Committee. Between 2012 and 2015 Erica served as Chief Examiner in Haematology for the Royal College of Pathologists of Australasia, and she was Associate Chief Examiner from 2008-2012. Erica is a founding member of 'Blood Matters', a Victorian Department of Health transfusion practice improvement collaborative, and between 2016-2013 she chaired its Serious Transfusion Incident Reporting (STIR) haemovigilance program. In 2013 Erica was awarded a Churchill Fellowship to support her work in patient blood management practice and research. The Transfusion Research Unit (TRU) at Monash University operates a number of regional and national registries to evaluate clinical practice and patient outcomes for important blood disorders, including massive transfusion, aplastic anaemia and other bone marrow failure syndromes, fetomaternal alloimmune thrombocytopenia (FMAIT), haemoglobinopathies (thalassaemia and sickle cell disease), thrombotic thrombocytopenic purpura (TTP), lymphoma and myeloma. The TRU also performs clinical trials, systematic reviews, health economics analyses and a number of other research and teaching activities across the spectrum of blood diseases. This work is supported by the NHMRC (including through a 5-year Synergy Grant 2020-2024), Medical Research Future Fund, national blood services, Australia's National Blood Authority, and a wide range of industry, community and philanthropic partners. In 2020, Erica was awarded the inaugural Fiona Stanley Prize from the NHMRC for the top-ranked Synergy grant application in 2019.
Professor Dr John Moore
St. Vincent's Health Network, Sydney, Australia
St. Vincent's Health Network, Sydney, Australia
JOHN MOORE MB.BS, MD, FRACP, FRCPA John Moore graduated from Sydney University in 1989. He trained in haematology at the Royal North Shore Hospital, The Westmead Children’s Hospital and conducted post graduate training in London. He was the bone marrow transplant co-ordinator at the Royal Free Hospital, London from 1997-98 before returning to Australia to conduct clinical and immunological research into haematopoietic stem cell transplant. He is a fellow of both the College of Physicians and Pathologists. He completed a Doctorate of Medicine at St. Vincents Hospital whilst researching the role of Haematopoietic Stem cell Transplantation for Severe Rheumatoid Arthritis. He is currently a Senior Staff Specialist in the Haematology Department at St.Vincents Hospital and a Visiting Medical Officer at St. Vincents Private Hospital. He was apointed Professor of Medicine (conjoint – UNSW) in April 2022 and The Chong Family Director of Cellular Therapies at St Vincents Hospital in July 2021. Dr Moore has extensive experience in stem cell transplantation and immunotherapy spanning over 25 years. He has been an active member of the stem cell transplant community in Australia and internationally. He was the Chair of the Bone Marrow Transplant Committee of the Australian Leukaemia and Lymphoma Group (ALLG) from 2004-2006. He is a member of the Auto-Immune Sub-Committee of the European Group for Blood and Marrow Transplantation (EBMT) and on the Worldwide Network for Blood and Marrow Transplantation (WBMT), Education and Dissemination Committee. He is on the scientific committee of the Asia-Pacific Blood and Marrow Transplantation group (APBMT). Dr Moore is the clinical lead of the NSW state wide service of stem cell transplantation for auto-immune diseases. This program is the largest in Australia and the second largest contributor to the EBMT database. He is the principal investigator of the Australian Haploidentical stem cell transplant trial currently being conducted from St Vincents Hospital and the Australasian Bone Marrow Transplant Recipeints Registry (ABMTRR). He has published extensively in the field of stem cell transplantation with over 100 publications in the area. He is team leader of the stem cell transplant group in the Blood Diseases and Cancer laboratory at the Lowy Packer building.
Professor Dr Kwong Yok Lam
Queen Mary Hospital, Hong Kong
Queen Mary Hospital, Hong Kong
Professor Kwong is Chief of the Division of Haematology, Oncology and Bone Marrow Transplantation at the Department of Medicine, School of Clinical Medicine, The University of Hong Kong. He is a Chui Fook-Chuen Professor in Molecular Medicine. He is specialized in haematology and haematopathology. His clinical work focuses on the management of haematological malignancies. His team has especial interests in the treatment of leukaemias and T-cell and natural killer cell malignancies. His research centres on the molecular pathogenetic pathways and novel treatment modalities in haematological neoplasms. Together with the clinical pharmacology team in his department, Professor Kwong has pioneered the development and use of oral arsenic trioxide in the treatment of acute promyelocytic leukaemia and other blood cancers. His research team is also actively involved in defining the molecular defects and optimal treatment protocols for T-cell and natural killer cell lymphomas, which are neoplasms prevalent in Asian populations.
Professor Dr Matthew J Matasar
Memorial Sloan Kettering Cancer Centre. New York, United States
Memorial Sloan Kettering Cancer Centre. New York, United States
Consultant Medical Oncologist/Haematologist & Medical Director of MSK Bergen Memorial Sloan Kettering Cancer Centre. Prof Matasar obtained his medical degree from Harvard Medical School, residency at Columbia University Medical Centre and fellowship in Medical Oncology/hematology at Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College. He was awarded the John J. Kenny Award by Leukemia & Lymphoma Society in 2017. Prof Matasar is a medical oncologist/hematologist who focuses on caring for patients with lymphoma. He is an associate editor of ASH clinical news and is an appointee for National Committee on Quality for American Society of Hematology (ASH). His research interests focus on improving our understanding of the long-term effects of lymphoma treatments, and on studying new ways to improve the quality of life for survivors of lymphoma. He is the section head for aggressive B-cell Lymphoma and is actively exploring new treatments in the management of high-risk aggressive lymphoma and certain uncommon types of non-Hodgkin lymphoma.
Professor Dr Martin Griesshammer
Johannes-Wesling Clinic Minden, Minden, Germany
Johannes-Wesling Clinic Minden, Minden, Germany
Medical Director in the Department of Haematology, Haemostaseology, Oncology and Palliative Care at the Johannes Wesling University Clinic in Minden. Chair of Internal Medicine at the Johannes Wesling University Clinic. Prior to this appointment, he was Vice Head of the Department of Haematology and Oncology at the University of Ulm. Under Professor Griesshammer’s guidance, the Johannes Wesling University Clinic in Minden serves many haematological patients, providing outpatients and inpatient services, peripheral blood stem cell transplantation, haemostaseology, oncology and palliative care.
Professor Dr Renato Bassan
Ospedale dell'Angelo, Mestre-Venezia, Venice, Italy
Ospedale dell'Angelo, Mestre-Venezia, Venice, Italy
Renato Bassan is Director of the Hematology Unit at Venice Hospitals, Italy. Dr Bassan obtained his degree in medicine and completed his postdoctoral fellowship in haematology at Padua University, Italy. He then started his work as full-time haematologist at Bergamo Hospital, Italy, where he set up the leukaemia diagnostic section, the autologous bone marrow transplantation section and the leukaemia clinics. Dr Bassan was trained in onco-haematology at St. Bartholomew’s Hospital in London, UK, lately reaching the position of Honorary Consultant. He assumed his current position in 2011. Dr Bassan’s main professional interest is therapy of acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia. He has led several prospective Phase 2 and 3 trials for the Northern Italy Leukemia Group (NILG), and is involved in new studies and collaborations with the Italian Group for Haematological Diseases in Adults (GIMEMA) and the European Working Group on Adult ALL (EWALL).
Professor Dr Roopen Arya
King's College Hospital, London, United Kingdom
King's College Hospital, London, United Kingdom
Roopen Arya is Clinical Director for Haematological Medicine at King’s College Hospital in London. He is also Director of King’s Thrombosis Centre and Professor of Thrombosis and Haemostasis at King’s. He trained at Oxford and King’s. His main interests are venous thromboembolism, thrombophilia, and women’s health. He is passionate about thrombosis research and advancing safety and quality of care through innovative and patient-centric approaches to thrombosis care. He is Director of the National VTE Exemplar Centres Network in England.
Professor Dr Sylvie Freeman
University of Birmingham, Birmingham, United Kingdom
University of Birmingham, Birmingham, United Kingdom
Sylvie Freeman is Professor of Immunohematology at the University of Birmingham, UK, honorary consultant haematologist at University Hospitals Birmingham and director of the University of Birmingham Clinical Immunophenotyping Service for the diagnosis and monitoring of hematological malignancies. Training as a hematologist and clinician scientist in Oxford with further clinical rotations at University College Hospital London and Bristol, UK focussed her interests onto predicting treatment resistance in acute myeloid leukemia and myelodysplasia when starting in Birmingham. Prof Freeman pioneered and implemented flow cytometric MRD methodology for the UK National Cancer Research Institute (NCRI) acute myeloid leukemia trials. This has generated an evidence-base for risk adaptive therapy in acute myeloid leukemia. She co-leads a combined immunophenotypic /molecular MRD monitoring strategy for the NCRI UK trials and provides the UK reference service for flow cytometric MRD in acute myeloid leukemia and myelodysplasia. Prof Freeman’s ongoing efforts to optimise the detection of residual leukemic cells and facilitate standard of care testing are strengthened by an international collaborative network that includes the UK NCRI AML Working Group, the European LeukemiaNet AML MRD Working Group and the American Society of Hematology International Consortium Acute Leukemia Laboratory Committee.
Professor Dr Xiao-Jun Huang
Peking University People's Hospital & Institute of Hematology, Beijing, China
Peking University People's Hospital & Institute of Hematology, Beijing, China
Chairman, Peking University Institute of Hematology Director, Department of Hematology, Peking University People's Hospital Director, Executive Committee of Asia Pacific Hematology Consortium Director, National Clinical Research Center for Hematologic Diseases, P.R.China Chairman, Chinese Association of Hematologists, CMDA Chairman, Committee of Experimental Hematology, Chinese Association of Pathophysiology Director, China Marrow Donor Program
Associate Professor Dr Elizabeth Tegg
ICPMR-NSWHP Westmead/University of Sydney, Sydney, Australia
ICPMR-NSWHP Westmead/University of Sydney, Sydney, Australia
Associate Professor Elizabeth Tegg is a dual trained pathologist in Haematology and Genetics. She is currently based at The Institute of Clinical Pathology and Medical Research, which is part of New South Wales Health Pathology at Westmead Hospital. She is head of department of both Hematology and Genetics where she oversees a busy tertiary referral laboratory as well as a network of Branch laboratories across NSW. She has undertaken a PhD in the genetic predisposition of Haematological malignancies and continues an active research interest in this field. Her area of interest is in the genetics of haematological malignancies.
Associate Professor Dr Koh Liang Piu
National University Cancer Institute, Singapore
National University Cancer Institute, Singapore
A/Prof Koh is the associate professor at the Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore. He is also the senior consultant at the Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS). As the clinical director of the NCIS adult Haematopoeitic Cell Transplant (HCT) program at NCIS. His research interest focuses mainly on clinical haematopoeitic stem cell transplantation, in particular alternative donor transplant using haploidentical and umbilical cord blood transplantation in treating haematological malignancies. He is the principal investigator of several international, multi-centre phase II/III clinical trials in the treatment of haematological malignancies, and infectious complications, and also several HCT studies addressing the use of umbilical cord transplant, alternative donor transplant, graft-versus-host disease (GVHD) treatment and prophylaxis, and novel approach in conditioning regimens. He has published more than 70 peer reviewed papers and 3 book chapters on the topic of HCT, and has also presented more than 20 abstracts in international haematology/HCT meetings
Associate Professor Dr Nada Hamad
Kinghorn Cancer Centre, New South Wales, Australia
Kinghorn Cancer Centre, New South Wales, Australia
A/Prof Nada Hamad is a senior staff specialist bone marrow transplant, cellular therapies, clinical and laboratory haematologist at St Vincent’s hospital in Sydney, where she is also director of the haematology clinical trials unit. She is President of Australia and New Zealand Transplant and Cellular Therapies and chairs a number of national and international committees in the field of transplantation and cellular therapies. She studied Medicine at the University of Sydney and completed her Haematology training in Sydney. Prior to her career in medicine, she completed a Bachelor of Science and Master of Science in Forensics, working in this field for a short period of time. She completed two post-graduate fellowships in BMT and lymphoma at the Princess Margaret Cancer Centre in Toronto Canada through the University of Toronto. She is an active clinical trialist and researcher with a special research interest in graft versus host disease. She is chair of the Australasian Leukaemia and Lymphoma Group transplant and cellular therapies working party and a member of the Scientific Advisory Committee. She is also a member of the National Blood Cancer Taskforce. A/Prof Hamad also has an academic interest in gender equity, diversity and inclusion in medicine (EDI). She is the deputy co-chair of the EDI in Medicine committee at the University of New South Wales in Australia the EDI lead for the Lancet Haematology amongst a number of other EDI committee leadership positions and memberships.
Associate Professor Dr Naval Daver
MD Anderson Cancer Center, Texas, United States
MD Anderson Cancer Center, Texas, United States
Dr Naval Daver is an associate professor and director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center (MDACC) in Houston, Texas, USA. He is a clinical investigator with a focus on molecular and immune therapies in acute myeloid leukemia (AML) and myeloid disease, and is principal investigator on more than 25 ongoing institutional, national, and international clinical trials in these diseases, including multiple registration and label enabling trials. These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune, and cytotoxic agents, and identifying and overcoming mechanisms of resistance. He is especially interested in developing monoclonal and bispecific antibodies, immune checkpoint, CD47, NK and T-cell based approaches, as well as combinations of targeted and apoptotic therapies in AML, and he is leading a number of these trials at MDACC. Dr Daver has published over 300 peer-reviewed manuscripts and is on the editorial board of numerous hematology journals. He also serves as Chair on numerous national and international meetings and educational platforms.
Associate Professor Dr Peter Mollee
Princess Alexandra Hospital Amyloidosis Centre, Queensland, Australia
Princess Alexandra Hospital Amyloidosis Centre, Queensland, Australia
MBBS(Hons), MMedSc, FRACP, FRCPA Cancer Services, Princess Alexandra Hospital School of Medicine, University of Queensland Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School. He is Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) where he also leads the Myeloma Working Party. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia, Australian Amyloidosis Network, National Blood Cancer Taskforce and chairs the AACB Monoclonal Gammopathy Working Group. Dr Mollee obtained a Masters in Clinical Epidemiology with a specialisation in Research Protocol Design and has a particular interest in amyloidosis and the plasma cell dyscrasias. He heads the Myeloma Service as well as the Queensland Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.
Assistant Professor Dr Francesca Lim
Singapore General Hospital, Singapore
Singapore General Hospital, Singapore
Assistant Professor Francesca Lim is a Consultant Hematologist at Singapore General Hospital and the Assistant Medical Director at the Cell Therapy Facility, Health Science Authority (HSA). Dr Lim is also the Principal Lead of Education and the Lead of Cellular Immunotherapy for adult blood cancers of the SingHealth Duke-NUS Cell Therapy Centre (SDCT). Dr Lim spent 2 years training at MD Anderson Cancer Center on CAR T cell therapy particularly on CAR NK cell therapy under Professor Katy Rezvani as well as in the Good Manufacturing Processing Facility (GMP). Since her return from MD Anderson Cancer Center, Dr Lim has been instrumental in supporting and coordinating the Cell Therapy Program at SGH Haematology, SingHealth, both at the clinical, research and translational level.
Dr Anna Sureda
Institut Català d'Oncologia-Hospitalet, Barcelona, Spain
Institut Català d'Oncologia-Hospitalet, Barcelona, Spain
Anna Sureda, (MD, PhD) is nowadays the Head of the Clinical Hematology Department of Institut Català d’Oncologia – Hospitalet, Barcelona. She had previously been a Senior Consultant in Hospital de la Santa Creu i Sant Pau, Barcelona (from January 1991 to December 2010) and a Senior Consultant focused in lymphomas and hematopoietic stem cell transplantation (HSCT) at Addenbrookes–Cambridge University Hospital, UK (December 2010 – December 2012). Anna Sureda has focused her career on clinical investigations into the treatment of Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and multiple myeloma patients evaluating novel therapies such as immunotherapy combined with stem-cell transplantation. Anna Sureda was appointed Chairperson of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT) from March 2004 to March 2010 and Secretary of the same organization from March 2010 to March 2016. She was elected co-chair of the Lymphoma Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR) and has served the organization in this position from February 2015 to February 2019. She was subsequently appointed as member of a large non-US Transplant Center in the Advisory Committee of the CIBMTR (from February 2019). Anna Sureda is President of the Spanish Society of Hematopoietic Stem Cell Transplantation and Cellular Therapy (GETH-TC) and, from March 2022, President of the EBMT. Anna Sureda is regular reviewer of several peer reviewed journals (Blood, Annals of Oncology, Bone Marrow Transplantation, The Hematology Journal, The European Journal of Hematology y Annals of Hematology) and has co-authored more than 400 manuscripts.
Dr Chen Yunxin
SingHealth Duke-NUS Blood Cancer Centre, Singapore
SingHealth Duke-NUS Blood Cancer Centre, Singapore
Dr. Chen is a Consultant Haematologist at Singapore General Hospital, and Clinical Deputy Lead (Adult Blood Cancer) and Co-Lead (Education) at the SingHealth Duke-NUS Cell Therapy Centre. She specialises in the care of patients with multiple myeloma and lymphoproliferative disorders. She completed her Health Manpower Development Programme on immunotherapy at the Memorial Sloan Kettering Cancer Center where she was involved in developing novel cellular therapeutics for treatment of multiple myeloma as well as myeloma CAR T cell clinical trials. She works with a dedicated team of physicians and allied health professionals in the Haematopoietic Stem Cell Transplant Programme at SGH to deliver CAR T cells to patients as well as to develop outpatient transplant services.
Dr Daryl Tan Chen Lung
Mount Elizabeth Novena Hospital, Singapore
Mount Elizabeth Novena Hospital, Singapore
Dr Daryl Tan is a haematologist at Mount Elizabeth Novena Hospital, Singapore. He trained in internal medicine and haematology at the Singapore General Hospital, and pursued postdoctoral training and clinical research in the field of lymphoma at Stanford University, USA. He was formerly the clinical lead for the lymphoma and myeloma services at the Singapore General Hospital, and spearheaded several clinical trials examining novel approaches in treating lymphoma and multiple myeloma. In 2011, Dr Tan helped set up a comprehensive haematology service and was the director of research at a private hospital in Singapore. He integrated research with clinical practice, availing novel therapeutics for cancer patients failing standards of care. He was an assistant professor at the Duke-NUS Graduate Medical School, and received several research grants from the National Medical Research Council, Singapore Health Foundation, and the Singapore Cancer Syndicate. He was elected into the International Myeloma Working Group in 2014 and also sits on the advisory panel of the International Myeloma Foundation’s Asia Myeloma Network. He has delivered more than 80 invited lectures on the treatment of lymphoma and multiple myeloma at international and regional conferences. Dr Tan is a board member of the Chapter of Haematologists and is appointed by the Ministry of Health as an advisor for the Residency Advisory Committee for Haematology training in Singapore. His continued affiliation with the academic hospitals allows him to contribute to post-graduate teaching, and to advise patients on participation in clinical trials for lymphoma and multiple myeloma. He was the principal investigator of more than 40 investigator-initiated and industry-sponsored clinical studies. His research has led to several international presentations and more than 100 publications in high-impact factor scientific journals including first-authored articles in the Lancet Oncology, Blood and the Annals of Oncology. His expertise in lymphoma and multiple myeloma was recognised by the publication of two lead-author review articles on their respective treatment guidelines in Lancet Oncology in 2014. Dr Tan’s work on immunotherapy in NK/T-cell lymphoma has led to its endorsement on the American NCCN cancer treatment guidelines in 2018. Dr Tan has received several awards including the Singapore Health Service Quality Service Gold Award in 2011 and the Courage Medal during the Singapore SARS epidemic in 2004.
Dr Drew Provan
The Royal London Hospital, London, United Kingdom
The Royal London Hospital, London, United Kingdom
I trained in molecular biology before studying medicine. After various junior medical posts I undertook research at Harvard Medical School. I have been a consultant in London since 2000. My primary clinical and research interest is immune thrombocytopenia. However as well as Clinical medicine I currently run a business which offers presentation coaching, slide design and illustration. I very much enjoy public speaking and helping others overcome their fears, designing better slides and generally improving their delivery. This is my primary focus at present .
Dr Kenichiro Hasumi
ICVS Tokyo Clinic, Tokyo, Japan
ICVS Tokyo Clinic, Tokyo, Japan
Dr. Kenichiro Hasumi of Tokyo, Japan is a physician, specialized in cancer immunotherapy and terminal care. He is also a researcher and visionary, focused on the development of cancer vaccines and improved clinical treatments to achieve better patient outcomes with a higher quality of life. He is devoted to his patients and their families, and to improved cancer education, understanding, and awareness on a global scale. In 1931, his late father Dr. Kiichiro Hasumi advanced the hypothesis of cancer propagation by virus and started studies to prove his theory. And after seventeen years of meticulous research and development efforts, the clinical application of the Hasumi Vaccine as the first and most used cancer vaccine in the history of medicine was started and has been clinically prescribed to more than 500,000 patients cumulatively till today for more than seventy years. In 1988 after completing his clinical training at the Institute of Medical Science, the University of Tokyo (IMSUT), Dr. Hasumi succeeded his father in this pioneering work to continue research and development, and the treatment of cancer patients. In 1999, Dr. Hasumi established the Hasumi International Research Foundation (HIRF) as a nonprofit organization in the United States HIRF has been sponsoring the International Cancer Vaccine Symposium since 2001. The primary purpose of HIRF is to conduct and support scientific research in connection with finding a cure for various forms of cancer, particularly with the use of immunotherapy. Dr. Hasumi has developed and patented a dendritic-cell-base cellar immunotherapy for advanced and recurrent cancer called HITV (Human Initiated Therapeutic Vaccine) therapy, aiming the complete remission of cancers. Currently, with his ever-growing vision to help cancer patients, Dr. Hasumi has been supporting various cancer researches in the United States, Japan, Taiwan, Malaysia, China and Germany.
Dr Ng Chin Hin
Gleneagles Hospital Singapore, Singapore
Gleneagles Hospital Singapore, Singapore
Dr Ng Chin Hin is a haematologist practising in Gleneagles Hospital, Singapore. He specialises in blood cancers such as leukaemia and he has a special interest in leukaemia stem cell and biomarker research, and targeted therapy in acute myeloid leukaemia. He is experienced in the treatment and management of a wide range of conditions like anaemia, bleeding disorders such as haemophilia, and other blood disorders like myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), thrombocytosis. Dr Ng was the leukaemia lead at National University Cancer Institute of Singapore (NCIS) and has more than 10 years experience in this field. He also served several years as the research director for the haematology division and chairperson for the leukemia tumour board in NCIS. Prior to joining Gleneagles Hospital, he was an assistant professor in the Department of Medicine in NUS and was actively involved in training the undergraduates there. Dr Ng has published many papers in the Journal of Clinical Pathology and other journals. He was active in clinical research and was the research director for the haematology division in the Department of Haematology-Oncology at NCIS.
Dr Rajat Bhattacharyya
KK Women's and Children's Hospital, Singapore
KK Women's and Children's Hospital, Singapore
MBBS MD DCH FRCPCH FRCPath. CCT in Haematology UK Consultant, Paediatric Haematology Oncology BMT KK Women’s and Children’s Hospital, Singapore Rajat did his undergraduate medical training and post graduate paediatric training (MD paediatrics) from Medical College Kolkata. Then he pursued his further paediatric and haematology training in UK 1998- 2010 working in different centres initially in general paediatrics and then haematology oncology. He completed Specialist Registrar training (CCT in Haematology UK). He also did 1 year post CCT fellowship in paediatric haematology oncology in Vancouver Children’s Hospital, Canada. Currently he is working as a senior consultant in KK Hospital since March 2013. His special interest is benign haematological conditions including ITP, bone marrow failure syndromes and also malignant haematological conditions including leukaemia and stem cell transplantation. He has initiated the Haploidentical stem cell transplantation programme in KK Hospital in Singapore with rapid evolution of the selective T cell depletion technique in the clinical practice.
Dr Robin Gasiorowski
Macquarie University, Sydney, Australia
Macquarie University, Sydney, Australia
Dr Robin Gasiorowski completed medical training at Cambridge University and University College London, before moving to Australia in 2004. Following specialist haematology training at Royal Prince Alfred and Concord hospitals he now works as a clinical and laboratory haematologist, with appointments at Concord and Macquarie University Hospitals. He has a particular interest in acute leukaemia and high-grade lymphoma and in 2017 completed his PhD with the Dendritic Cell Research group at the University of Sydney, developing novel therapeutic antibodies for the treatment of Acute Myeloid Leukaemia (AML). Whilst he continues to be contribute to this group’s work, he also has a strong interest in clinical research, particularly in the development of novel immune therapies for patients with haematological malignancies. He has been a principal investigator on a number of industry and ALLG sponsored clinical trials for patients with high grade lymphoma and leukaemia.
Ms Julija Sipavicius
Royal North Shore Hospital, Sydney, Australia
.jpg)
Royal North Shore Hospital, Sydney, Australia
Julija is a registered nurse with over 20 years experience in the field of haematology and blood and marrow transplant (BMT) nursing. Having trained in Australia Julija spent 8 years working at the Hammersmith Hospital in London UK where she further established her interest in BMT and undertook a range of post graduate advanced haematology nursing courses. On returning to Australia Julija took a short break from the clinical area, working with the BMT Network of NSW coordinating an acuity research project then as Haematology/BMT content author for the Cancer Institute of NSW. Julija returned to the clinical area as a senior nurse, completing a Masters Degree in Nursing Leadership and then moving to the Royal Melbourne Hospital Clinical Haematology and BMT services as the BMT coordinator, and more recently as a BMT Nurse Practitioner. During this time she successfully completed a second Masters degree in Nurse Practitioner. She is a founding member of the Haematology Society of Australia and New Zealand (HSANZ) Nurses Group, past secretary and co-editor for the HSANZ NG newsletter, and she is an affiliate lecturer at the University of Sydney. Julija currently works as the Haematology/BMT Nurse Practitioner at the Royal North Shore Hospital in Sydney. Again her core clinical work is in BMT with a focus on post-transplant care and long term follow-up, in addition to managing patients with Multiple Myeloma.
Emeritus Professor Dr Cheong Soon Keng
Universiti Tunku Abdul Rahman, Kuala Lumpur, Malaysia
Universiti Tunku Abdul Rahman, Kuala Lumpur, Malaysia
Professor Cheong is Senior Professor and Dean of the Faculty of Medicine & Health Sciences, Universiti Tunku Abdul Rahman (UTAR), since November 2009. He is currently the Visiting Consultant Haematologist at the Sungai Long Specialist Hospital, Kajang and Brighton Medical Centre, Cyberjaya. He received his basic medical degree (MBBS) from the University of Malaya in 1975, and obtained his postgraduate qualifications in internal medicine MRCP (UK), clinical pathology DCP with distinction (University of London), haematology FRCPA (Australasia) in 1978, 1979 and 1992 respectively. He was elected to fellowship FRCP (Edinburgh and Glasgow) in 1990, FAM (Malaysia) in 1997, and FAM (Singapore) in 2011. For his research contribution, he was elected Fellow of the Academy of Sciences of Malaysia in 2001 and Founding Fellow of the Faculty of Sciences, RCPA (Australasia) in 2011. He was conferred the honorific title, Professor Emeritus, by the National University of Malaysia in 2007. In 2011, he was appointed Honorary Professor of Universiti Malaya and Senior Fellow of the Academy of Sciences of Malaysia which carries the title “Academician”. Being an active researcher in basic sciences and clinical haematology, he has authored or co-authored over 500 publications and presentations. He has won numerous research grants and presentation awards. His current research interest is in blood disorders, immunotherapy for cancers, and the application of mesenchymal stem cell and induced pluripotent stem cells in reparative medicine. He supervised or co-supervised 50 Master and 21 PhD theses by research to date. Presently he also serves as the President of the College of the Pathologists, Academy of Medicine of Malaysia and the Vice-President of the National Cancer Council (MAKNA). He is also an Emeritus Member of the American Society of Hematology.
Professor Dr S Fadilah Abdul Wahid
Pusat Terapi Sel-UKM, Kuala Lumpur, Malaysia
Pusat Terapi Sel-UKM, Kuala Lumpur, Malaysia
Senior Consultant Haematologist Head of Pusat Terapi Sel Professor Dr S Fadilah is Senior Consultant Haematologist and Transplant Physician at Universiti Kebangsaan Malaysia Medical Centre (UKMMC) as well as Head of Pusat Terapi Sel, Hospital Canselor Tuanku Muhriz (HCTM). She is currently a Professor of Medicine (Internal Medicine & Haematology) at the Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM). She received her basic medical degree and Masters in Internal Medicine from the UKM Kuala Lumpur. In 2005, she completed her PhD Degree in Cancer Immunotherapy from the University of Queensland Mater Medical Research Institute in Australia. She had undergone numerous training programs in blood and marrow transplantation in the UK, Japan and Australia. She is a fellow of the Royal College of Physicians (RCPE) Edinburgh. She has been actively involved in basic translational research in hematological malignancies, with a particular niche focus on dendritic cell and stem cell therapy and has been appointed as the principle investigator of numerous investigator initiated (industry-sponsored) clinical trials. She is currently the principal investigator for clinical trials involving dendritic cell-based treatment and CAR-T cell treatment for lymphoma and leukemia for patients in Malaysia. Being an active researcher in basic sciences and clinical haematology, she has authored or co-authored over 100 publications in peer-reviewed scientific journals for hematological and non-hematological disorders, more than 100 scientific presentations, consensus and clinical practice guidelines and monographs. As a result of collaboration with external medical institutions and industry partners, she has raised large research funds amounting up to RM 20 million and set up several research groups. She is an editorial board member of several local and international journals and an author for Cochrane systematic review, UK. She supervised and co-supervised 28 Master, 5 Clinical Hematology Subspecialty Program and 2 PhD theses to date. She has served as a member of Asia-Pacific boards for multiple myeloma, lymphoma and others . She is also a trainee and examiner in the clinical hematology subspecialty training program and evaluator of the clinical hematologist recognition process in the country. Her expertise experience in the field of cell therapy and blood cancer in the country was recognized when she was appointed as a member of the National Transplant Council, Pharmaceutical Control Bureau, National Science & Research Council and National Stem Cell Committee, MOSTI research proposal panel, MAKNA consultant, Inno Bio Diagnostics, as well as as a manager and advisor to several private biotech companies. Most recently, in 2019, she was appointed as a project leader for the establishment of the International Cancer Vaccine Kuala Lumpur Clinic with full sponsorship from ICVS Tokyo, HIRF.
Professor Dr Bee Ping Chong
University of Malaya Medical Centre, Kuala Lumpur, Malaysia
University of Malaya Medical Centre, Kuala Lumpur, Malaysia
Dr Bee is a Consultant Haematologist and a lecturer and Professor at the Faculty of Medicine, University of Malaya (UM) and the University of Malaya Medical Centre. He is a member of the Malaysian Medical Association, the Malaysian Society of Haematology and the European Society of Haematology. He has authored or co-authored many peer-reviewed journal articles and meeting abstracts in the field of Haematology. Professor Bee specialized in Haemato-Oncology (Myeloproliferative Disorders, Multiple Myeloma, Lymphomas, Leukaemias, Myelodysplastic syndrome), non-Malignant Haematological disorders (bleeding disorders, Thrombosis and Anticoagulation, Anaemias, Idiopathic thrombocytopenic purpura), Haemoglobinopathy (Thalassaemia, Sickle cell anaemia), paroxysmal nocturnal haemoglobinuria, thrombotic thrombocytopenic purpura and haematopoietic stem cell/bone marrow transplant.
Professor Dr Noraidah Masir
Hospital Canselor Tuanku Muhriz, Kuala Lumpur, Malaysia
Hospital Canselor Tuanku Muhriz, Kuala Lumpur, Malaysia
Prof. Dr. Noraidah graduated from the Royal College of Dublin, Ireland in 1986 with MBBCh. BAO, LRCP & SI. She then pursued her studies in Master of Pathology (MPath) in Universiti Kebangsaan Malaysia (UKM) in 1994. In 2007, she obtained D.Phil. (Oxon) from the University of Oxford. Currently, Prof. Dr. Noraidah is a Visiting Consultant Pathologist (Histo and cytopathology) at Pantai Premier Pathology. Prof. Dr. Noraidah also leads the Department of Pathology, Faculty of Medicine (UKM) since 2013. Previously in 1986, she served Hospital Kuala Lumpur as a House Officer and Hospital Tuanku Jaafar, Seremban as a Medical Officer in 1987. Her interest in academic started in 1990 as a Trainee Lecturer in Faculty of Medicine, UKM. After obtaining her Master in Pathology in 1994, she served few government hospitals as an Anatomical Pathologist. Her wide interest has brought her to have a clinical attachment in Haematopathology, John Radcliffe Hospital in the University of Oxford, United Kingdom. In 2007, she completed her PhD thesis in Immunogenotypic studies of human lymphomas. Her extensive experiences include: • Co-Chairperson (Education Committee), College of Pathologists AM (Malaysia), • Invited Lecturer for various local & international scientific symposiums and conferences, • External Examiners for research studies in several universities and organiser of Professional courses & meetings, • Vetting Panel for research proposals for MAKNA Cancer Research Awards and Research Grants by Ministry of Higher Education (MOHE) Malaysia, • Life member of College of Pathologists Academy of Medicine, • Life Member of Royal College of Surgeon in Ireland Alumni, • Life member of University of Oxford Alumni, • Member of European Association of Haematopathology. Till now, Prof. Dr. Noraidah has published more than 40 research publications, presenting of more than 27 studies and review of more than 9 scientific manuscripts.
Professor Dr Raja Zahratul Azma Raja Sabudin
Hospital Canselor Tuanku Muhriz, Kuala Lumpur, Malaysia
Hospital Canselor Tuanku Muhriz, Kuala Lumpur, Malaysia
Dr Raja Zahratul Azma is a Professor of Haematologist with subspecialisation in Molecular Genetic of Haematology Disorders. She has led multiple research projects in the field of haematology covering a wide variety of topics. Her main scientific interests are in blood cell disorders and molecular genetics of haematology diseases with her current researches is centred on thalassaemia, G6PD deficiency, leukaemia and digital haematology. She is presently committee member of Haematology Chapter of College of Pathologist and Human Variome Project Malaysian & South-East Asian Node; and Executive Committee Member of Global Globin Network.
Associate Professor Dr Ikmal Hisyam Bakrin
Universiti Putra Malaysia, Selangor, Malaysia
Universiti Putra Malaysia, Selangor, Malaysia
Ikmal Hisyam Bakrin, M.D. Consultant Dermatopathologist and Medical Lecturer in the Faculty of Medicine and Health Sciences, Universiti Putra Malaysia. He is practicing in HPUPM and Hospital Serdang as well as a visiting pathologist in Pantai Premier Pathology and Hospital Canselor Tuanku Muhriz UKM (HCTM). He is one of the expert persons for skin pathology in Malaysia and actively involved in dermatopathology clinicopathological conferences (CPCs), seminars, workshops, as well as conferences at national and international levels (Asian Society of Dermatopathology).
Associate Professor Dr Ramliza Ramli
Hospital Canselor Tuanku Muhriz, Kuala Lumpur, Malaysia
.jpg)
Hospital Canselor Tuanku Muhriz, Kuala Lumpur, Malaysia
Assoc. Prof. Dr. Ramliza Ramli started her career as a lecturer and clinical microbiologist consultant with special interest in antimicrobial stewardship, antibiotic resistance and diagnostic bacteriology over 15 years of experience. She had short-course trainings in antimicrobial stewardship at Taiwan (2006) and Singapore (2017). She has combined her expertise with being appointed as a member of National Antibiotic Resistance Committee, Antibiotic and Infection Control Committee and Antimicrobial Stewardship Committee HCTM UKM. She currently serves as the Head of Bacteriology Unit at the Department of Diagnostic Laboratory Services. She is the internal auditor for Malaysia Society of Infectious Diseases & Chemotherapy (MSIDC), former member of Malaysian Medical Association Foundation Infectious Disease Fund and life-member of the Malaysia Medical Association.
Associate Professor Dr Wan Fariza Wan Jamaludin
Pusat Terapi Sel, HCTM, Kuala Lumpur, Malaysia
Pusat Terapi Sel, HCTM, Kuala Lumpur, Malaysia
Prof Madya Dr Wan Fariza Wan Jamaludin is a consultant physician and clinical haematologist with a deep interest in lymphoproliferative disorders and stem cell transplantations. She was medically trained in the UK and is extensively involved in hematological research with publications in Q1 journals.
Associate Professor Ir Ts Dr Mohd Ridzuan Ahmad
Universiti Teknologi Malaysia, Johor, Malaysia
Universiti Teknologi Malaysia, Johor, Malaysia
I obtained my Dr. Eng. (Micro-nano Systems Engineering) from Nagoya University, Japan in March 2010. I was a research officer in the Department of Robotics and Mechatronics, UTM, from June to November 2002. In 2003, I joined the Faculty of Electrical Engineering as a lecturer. I was promoted as a senior lecturer in 2011. Since 2011, I am a Principal Researcher at the Institute of Ibnu Sina, UTM and from 2014 as an Associate Researcher at the Advanced Photonics Science Institute in UTM. I was promoted to an Associate Professor in June 2017. In teaching, I have taught at the Faculty of Electrical Engineering, Universiti Teknologi Malaysia for fifteen years. I teach core and elective subjects that are related to the electrical engineering at the undergraduate and postgraduate levels. My research interests include multi-agent robotics system, micro/nanomanipulation, nanobiology, nanodevices, and single-cell analysis. I am a member of several professional engineering bodies such as the Institute of Electrical and Electronics Engineers (IEEE), Institute of Engineering and Technology (IET), a life member of Golden Key International Honor Society, a professional engineer of Board of Engineers Malaysia (BEM), a charted engineer of UK engineering council (IET) and a corporate member of Institute of Engineers Malaysia (IEM).
Dr Ng Soo Chin
Subang Jaya Medical Centre, Selangor, Malaysia
Subang Jaya Medical Centre, Selangor, Malaysia
Dr Ng Soo Chin is currently the Consultant Haematologist and Director of Clinical Diagnostic laboratory at Subang Jaya Medical Centre. He was the past President of MSH and Asean Federation of Haematology. He is an avid researcher and has presented and published 245 scientific papers.
Dato' Dr Chang Kian Meng
Sunway Medical Centre, Selangor, Malaysia
Sunway Medical Centre, Selangor, Malaysia
Dato’ Dr Chang is a consultant hematologist and transplant medicine at Sunway Medical Center. He was the Head of the Department and National Advisor for Haematology at the Ministry of Health for 13 years from 2004-2017. He is board certified by Fellow of Royal College of Physicians (UK), Fellow of Royal College of Pathologists Australasia and the National Specialist Register in Clinical Haematology and Haematology (Pathology). His clinical focus is on red cell and platelet disorders, leukaemias, MDS, lymphomas, multiple myeloma, clotting and bleeding problems, and consultative haematology. He is active in association activities; one of which is that he is a Member of the Asian Lymphoma Study Group and is the Past Chairman of the Medical Research Ethics Committee among others. His procedure focuses on blood and marrow stem cell transplantation, autologous transplants, and allogeneic transplants including sibling donors, unrelated donor, haplo donor and cord blood transplants.
Dato' Dr Suresh Kumar Chidambaram
Sungai Buloh Hospital, Selangor, Malaysia
Sungai Buloh Hospital, Selangor, Malaysia
Dr Suresh Kumar is currently the Head of the Department of Medicine and an Infectious Diseases consultant at Hospital Sungai Buloh, Malaysia. Dr Suresh graduated with an MBBS from the University of Kerala, India in 1993. He then obtained his MRCP (UK) in 1999 from the Royal College of Physicians in UK and Postgraduate diploma in epidemiology in 2009 from London school of Hygiene and Tropical Medicine. He obtained his infectious diseases training in Hospital Kuala Lumpur and Alfred Hospital, Melbourne, Australia. He has been Infectious Diseases Consultant in Hospital Sungai Buloh since 2003. He is also a visiting consultant for National Heart Institute (IJN). He serves on expert panels for national treatment and practice guidelines relating to infectious diseases including COVID-19, HIV, Dengue, Adult Immunisation, and National antibiotic guidelines. Dr Suresh is actively involved in the Infectious diseases fellowship programme in the country. He is the Past President of the Malaysian Society for HIV Medicine, MASHM.
Dato' Dr Goh Ai Sim
Hospital Pulau Pinang, Pulau Pinang, Malaysia
Hospital Pulau Pinang, Pulau Pinang, Malaysia
Dato’ Dr Goh Ai Sim (Senior Consultant Haematologist & Head of Dept of Medicine, Hospital Pulau Pinang) Dato’ Dr Goh Ai Sim graduated from University of Malaya in 1991 and did her haematology training in Hospital Kuala Lumpur and Royal Perth Hospital, Australia. She is currently the National Head of Haematology Service in Ministry of Health, Malaysia as well as Penang state advisor for haematology service. She is a Council member in the Malaysian Society of Haematology, chairperson for the MSH training committee and the NSR subcommittee for clinical haematology. She is actively involved in multiple clinical trials related to thalassaemia, hemophilia, leukaemia and PNH.
Dr Abu Dzarr Abdullah
Universiti Sains Malaysia, Kelantan, Malaysia
Universiti Sains Malaysia, Kelantan, Malaysia
Graduated from UKM medical school in 1994. Worked as Medical MO in several hospitals Taiping, Pulau Pinang, Alor Setar and Kubang Kerian before completing MMed in 2002. Joined USM as medical lecturer since 2003. Has been practicing clinical haematology in HUSM since then, as well as teaching and research in internal medicine and haematology. Main interest has been developing medical applications for service as well as teaching and learning.
Dr Birinder Kaur Sadu Singh
Hospital Canselor Tuanku Muhriz, Kuala Lumpur, Malaysia
Hospital Canselor Tuanku Muhriz, Kuala Lumpur, Malaysia
Birinder Kaur Sadu Singh B.Pharm (Hons), PhD (UKM) Senior Pharmacist, Pharmacy Department, Universiti Kebangsaan Malaysia Medical Centre Dr. Birinder Kaur currently heads the Cytotoxic Drug Reconstitution (CDR) and Parenteral Nutrition Services in UKMMC. Aside from clinical routines, she is also an Associate lecturer with the Faculty of Pharmacy in Universiti Kebangsaan Malaysia. As an experienced senior pharmacist, she is actively involved in training pharmacists and pharmacy assistants from all over the country including Ministry of Health and Private hospitals.on setting up CDR units and safe handling of cytotoxic drugs. She has presented her work locally and in international meetings. In addition, she is an active member of Parenteral & Enteral Nutrition Society of Malaysia, TheInternational Society of Oncology Pharmacy Practitioner (ISOPP) and The International Society of Renal Nutrition and Metabolism (ISRNM). Her areas of research interest includes Safe Handling of Cytotoxic Drugs, Immunonutirition in Critically Ill Patients and Malnutrition in Patients Undergoing Haemodialysis.
Dr Chin Sze Piaw
CMH Specialist Hospital, Negeri Sembilan, Malaysia
CMH Specialist Hospital, Negeri Sembilan, Malaysia
Dr Chin Sze Piaw qualified with an MBBS from Newcastle UK in 1995 and obtained his MRCP in 1998. He is currently a consultant physician and cardiologist at the CMH Specialist Hospital and Honorary Fellow of the Centre for Stem Cell Research, Faculty of Medicine & Health Sciences, Universiti Tunku Abdul Rahman. Dr Chin has served on expert committees for clinical practice guidelines, and several research and registry steering committees for cardiovascular disease and stem cell research. His own research interest in heart failure and stem cell therapy has led to over 60 publications in international peer-reviewed journals and presentations at international medical conferences. Among the cutting-edge research includes the demonstration of clinical anti-inflammatory and immunomodulatory actions of mesenchymal stem cells (MSC) and successful treatments of cardiomyopathy, stroke and diabetes complications and osteoarthritis. Dr Chin was jointly awarded patents from the USA for his pioneering use of MSC treatment for acute stroke, vernal keratoconjunctivitis and diabetes. His other patents include use of stem cells for severe heart failure, auto-immune disease, pre-diabetes and diabetes complications, and macular oedema. Dr Chin has been a joint recipient of numerous grants for his stem cell research including the ERGS and FRGS grants from the Ministry of Higher Education, the MOSTI Technofund, The Impak Perdana award and the Toray Foundation award from Japan. In 2018, Dr Chin and colleagues obtained another landmark approval from the regulatory authorities under the Ministry of Health, to undertake a large multicenter clinical trial of acute Graft versus Host Disease (aGVHD). In 2021, Dr Chin was one of several experts from Asia to discuss about use of MSC for COVID-19. Dr Chin Sze Piaw leads the regulatory, pre-clinical and clinical research activities at Cytopeutics.
Dr Habsah Aziz
Hospital Canselor Tuanku Muhriz, Kuala Lumpur, Malaysia
Hospital Canselor Tuanku Muhriz, Kuala Lumpur, Malaysia
Dr Habsah Aziz obtained her first degree in Biomedical Sciences from University Putra Malaysia in 2002. She then pursued her studies in Master of Biotechnology from Universiti Malaya and PhD in Molecular Medicine from Universiti Kebangsaan Malaysia with a thesis entitled molecular mechanism of relapse in childhood AML. She started her career as scientific officer in the Department of Diagnostic Laboratory Services, Hospital Canselor Tuanku Muhriz in 2002. Currently, Dr Habsah Aziz is a Senior Chief Scientific Officer in the Stem Cell Transplant Unit. Aside from clinical routines, she is also a Technical Assessor for laboratory accreditation scheme of Malaysia Medical Testing MS ISO 15189 for Standard Malaysia since 2013. Dr Habsah Aziz is also actively involved in quality activity namely quality control circle (KIK) and Malaysian Society For Quality In Health (MSQH).
Dr Henning Loo Cheng Kien
Sunway Medical Centre Velocity, Selangor, Malaysia
Sunway Medical Centre Velocity, Selangor, Malaysia
Dr Henning Loo Cheng Kien is a Clinical Haematologist at Sunway Medical Centre Velocity, Subang Jaya in Malaysia. He is a member of the Malaysia Society of Haematology (MSH). He did his postgraduate training at University of Malaya and received the Certificate of Specialist Training in Haematology from MSH. His clinical focus are on, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic syndrome, Myeloproliferative neoplasm, Haematopoietic stem cell transplant, Bleeding disorders, Anaemia, Venous-thromboembolism and Thalassaemia. In 2019, he have received the Gold award for best clinical abstract at 16th MSH Annual Scientific Meeting. His procedure focuses on Chemotherapy,, Immunotherapy, Targeted therapy, Bone marrow aspirate and trephine, Blood transfusion, Intravenous iron and Haematopoietic stem cell transplant.
Dr Jameela Sathar
Ampang Hospital, Selangor, Malaysia
Ampang Hospital, Selangor, Malaysia
Dr Jameela Sathar is a Consultant Haematologist and former Head of Department of Haematology at Ampang Hospital, Malaysia. Her field of interests are thalassaemia, haemophilia, thrombosis, bleeding disorders and patient blood management (PBM). She is the current President of the Malaysian Society of Patient Blood Management. Dr Sathar is a well-known speaker at both national and international medical conferences and hosts regular educational workshops for fellow medical doctors on the topic of PBM. Dr Sathar hopes that inappropriate transfusions of blood and blood components will be reduced with the practice of PBM.
Dr Jerome Tan Tsen Chuen
Ampang Hospital, Selangor, Malaysia
Ampang Hospital, Selangor, Malaysia
Dr Jerome Tan is the consultant clinical haematologist currently based in Hospital Ampang Selangor, which is the national referral haematology centre for the Ministry of Health, Malaysia. He is also the Head of the CRC Unit in Hospital Ampang and a clinical trainer for the MOH haematology subspecialty programme. He graduated from University of Malaya and obtained his postgraduate MRCP(UK) qualification from the Royal College of Physicians and Masters of Internal Medicine from the National University of Singapore. He is a former council member of Malaysian Society of Haematology and an honorary member of the Asia Pacific Leukaemia Consortium. His area of interest is mainly in malignant haematology namely in leukaemias, lymphomas & myeloma.
Dr Lam Chee Loong
University of Malaya Medical Centre, Kuala Lumpur, Malaysia
University of Malaya Medical Centre, Kuala Lumpur, Malaysia
Dr Lam is a Senior Lecturer and Consultant in Palliative Medicine at the University of Malaya. He received a CCT in Palliative Medicine from the Northern Deanery in the UK and worked at the Northern Centre for Cancer Care and the Marie Curie Hospice in Newcastle prior to returning to Malaysia. His main interests are in education, end of life care ethics and strategic development of palliative care nationally. He has published many studies on end of life care among patients and caregivers, as well as among the doctors in University of Malaya Medical Centre. He also received the Excellence Service award from University of Malaya in 2016. In the past few years, he was the Chairperson of Malaysian Hospice Council, from 2018 to 2020. He was also the Committee Member (Medical Advisor) to Assisi Palliative Care, from 2018 to 2019.
Dr Lavitha Sivapatham
Ampang Hospital, Selangor, Malaysia
Ampang Hospital, Selangor, Malaysia
Dr Lavitha Sivapatham is a Consultant Obstetrician & Gynaecologist, Paediatric & Adolescent Gynaecologist and Reproductive Medicine Specialist, who underwent training at the Royal Children’s Hospital, Melbourne who is currently attached to Hospital Ampang.
Dr Lew Kian Nian
Health Informatics Center, Planning Division, Ministry of Health, Kuala Lumpur, Malaysia
Health Informatics Center, Planning Division, Ministry of Health, Kuala Lumpur, Malaysia
As a Principal Assistant Director at the Health Informatics Centre, Ministry of Health Malaysia, Dr Lew is involved in the development, operation and maintenance of patient registry systems, together with a team consisting of IT officers and statisticians.
Dr Lim Soo Min
Sultanah Aminah Hospital, Johor, Malaysia
Sultanah Aminah Hospital, Johor, Malaysia
Dr Lim Soo Min is currently a consultant haematologist at Hospital Sultanah Aminah. He had received his training in clinical haematology at Hospital Ampang in 2007 and also a one year clinical attachment at Peter MacCallum Cancer Centre, Melbourne in 2010.
Dr Nor Hafizah Ahmad
National Blood Centre, Kuala Lumpur, Malaysia
National Blood Centre, Kuala Lumpur, Malaysia
Dr. Nor Hafizah Ahmad is a Transfusion Medicine Specialist who is currently the Head of Clinical Transfusion Division in National Blood Centre, Kuala Lumpur, Malaysia heading both Immunohematology and Clinical Transfusion Laboratory. She has completed her subspecialty training in Patient Blood Management/Clinical Transfusion and Immunohematology in Sweden recently and has been regularly involved in conducting training around the country for many years in both areas. She has been appointed as the chairperson for National Rare Donor Program since 2014 and is actively involved in the implementation of Patient Blood Management and Massive Transfusion Protocol in her place. Apart from that she had also been invited as speaker in various conferences at national and international level.
Dr Mohd Haris Fadzillah Abdul Rahman
Subang Jaya Medical Centre, Selangor, Malaysia
Subang Jaya Medical Centre, Selangor, Malaysia
Dr Mohd Haris Fadzillah Bin Abdul Rahman is a Consultant Physician and Haematologist at Subang Jaya Medical Centre, Malaysia. He has done his post-graduate clinical training at the Royal College of Physicians of Edinburg (MRCP) and received his board of certification in Internal Medicine from the Royal College of Physicians, the United Kingdom in 2003. Dr Mohd Haris’s procedures focus on Bone marrow aspiration and trephine biopsy as well as Cancer treatment, Stem cell transplantation. He is a council member of the Malaysian Society of Haematology (MSH) and a member of the Malaysian Society of Transplantation (MST).
Dr Mohammad Firdaus Abdul Aziz
Faculty of Law, University of Malaya, Kuala Lumpur, Malaysia
Faculty of Law, University of Malaya, Kuala Lumpur, Malaysia
Mohammad Firdaus Abdul Aziz is a senior lecturer and a program coordinator of Bachelor of Jurisprudence at the Faculty of Law, Universiti Malaya (UM). His current research interests are in the area of medical law, biosafety law, legal and ethical issues of emerging technologies such as stem cell technology, gene editing, and biobanking. He obtained his BSc (Hons) in Genetics and Molecular Biology from UM. He was awarded the National Science Fellowship to further his studies in MA in Biotechnological Law and Ethics at the University of Sheffield. He later went on to read DPhil in Public Health at St Edmund Hall, University of Oxford. In Oxford, he was based at the Centre for Health, Law and Emerging Technologies to pursue his interest in stem cell law and ethics. He has been involved in developing Bioethics in the Southeast Asia region as a UNESCO Bioethics Trainer. He is also a co-investigator of the UK Wellcome Trust to establish a regional bioethics network between Malaysia, Singapore, and Thailand and a co-investigator of the NIH Fogarty grant to develop a Master of Health Research Ethics at UM, the first of its kind in the region.
Dr Sharifah Shahnaz Syed Abd Kadir
Ampang Hospital, Selangor, Malaysia
Ampang Hospital, Selangor, Malaysia
DR. SHARIFAH SHAHNAZ BINTI SYED ABD KADIR graduated with MD from University Kebangsaan Malaysia in 2005 and subsequently obtained her postgraduate studies in Internal Medicine from the Royal College of Physicians (MRCP, UK) in 2009. She completed her fellowship in Clinical Haematology in 2017. During her fellowship, she received training in the field of stem cell transplantation from Eppendorf Medical Center, Hamburg, Germany. She currently serves as Haematologist managing general haematology and stem cell transplant cases in Ampang Hospital since 2014. She is actively involved in clinical research and very much interested in malignant haematology.
Dr Tan Sen Mui
Ampang Hospital, Selangor, Malaysia
Ampang Hospital, Selangor, Malaysia
Dr Tan Sen Mui obtained her basic medical degree locally and MRCP in UK. Started haematology training in the MOH in 2001 and subsequently further has her training in stem cell transplantation followed by research in cancer immunotherapy in University Wuerzburg, Germany. She has special interest in cancer immunotherapy and actively participated in clinical trials. Currently, she is the senior consultant haematologist & HOD of the Haematology Department in Hospital Ampang, which is the main haematology referral centre in Malaysia. She is also the past secretary of Malaysian Society of Haematology (MSH) and member of the European Society for Blood and Marrow Transplantation (EBMT).
Dr Thanuja Mahaletchumy
Hospital Canselor Tuanku Muhriz, Kuala Lumpur, Malaysia
Hospital Canselor Tuanku Muhriz, Kuala Lumpur, Malaysia
Dr Thanuja Mahaletchumy is a consultant nuclear medicine physician and currently the head at Department of Molecular Imaging and Nuclear Medicine, Universiti Kebangsaan Malaysia Medical Center. Her main expertise is in hybrid PET/CT and SPECT/CT imaging, with a focus on oncologic imaging. She also has special interest in radionuclide therapy.
Dr Veena Selvaratnam
Ampang Hospital, Selangor, Malaysia
Ampang Hospital, Selangor, Malaysia
Dr Veena Selvaratnam is a Haematologist based in Hospital Ampang. She completed her MRCP Uk in 2009 and her FRCPath (Hematology) in 2019. She underwent her Haematology sub-speciality training in 2013 -2017 during which she spent a one-year stint at the Hammersmith Hospital London to gain more experience in managing patients with bleeding and clotting disorders. She is currently in charge of the Haemophilia and bleeding disorder clinic and the Clinical Haematology Reference Laboratory in Hospital Ampang. She is also actively involved in clinical trials and education programs. Her areas of interest are bleeding disorders including acquired bleeding disorders, obstetric haematology as well as thrombophilia.
Dr Toh See Guan
Tuanku Ja’afar Hospital, Negeri Sembilan, Malaysia
Tuanku Ja’afar Hospital, Negeri Sembilan, Malaysia
Dr Toh did his clinical hematology training at Hospital Pulau Pinang and Hospital Ampang from 2011 till 2014. He is now working as clinical hematologist at Hospital Tuanku Ja'afar Seremban.
Ms Nik Syazana Izyan Saffery
Cytopeutics Sdn Bhd, Selangor, Malaysia
Cytopeutics Sdn Bhd, Selangor, Malaysia
- Graduated from pioneer batch of Masters in Regenerative Medicine from National Orthopaedic Centre of Excellence in Research and Learning (NOCERAL), University of Malaya. - Currently working as Projects Coordinator at Cytopeutics Sdn Bhd, managing and overseeing stem-cell based clinical trials in collaboration with MOH hospitals and funded by MOSTI.
Mr Timothy Lim Say Wai
Plutonet Sdn Bhd, Selangor, Malaysia
.jpg)
Plutonet Sdn Bhd, Selangor, Malaysia
Mr Timothy has been involved in manufacturing of cell therapy product for the past 10 years and has experience in various types of cell culture such as Cytotoxic T-cells, NK cells and CAR-T cells. He is currently involved in CAR-T cells manufacturing at Plutonet Sdn Bhd.
